CAC 40
7 688,27 +59,70 (+0,78 %) Euro Stoxx 50
4 941,08 +33,78 (+0,69 %) Dow Jones
39 150,33 +15,53 (+0,04 %) EUR/USD
1,0741 +0,0044 (+0,41 %) Gold future
2 339,90 +8,70 (+0,37 %) Bitcoin EUR
56 894,42 -3 058,20 (-5,10 %)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com
Secteur(s):
Secteur d’activité:
Employés à temps plein: 13 677
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Regeneron Pharmaceuticals, Inc. en date du 1 juin 2024 est 10. Les scores principaux sont Audit : 8; Société : 10; Droits des actionnaires : 10; Compensation : 9.
